Phillip Samayoa

Phillip Samayoa is a prominent figure in the biotechnology sector, currently serving as the Co-Founder and Chief Strategy Officer at Generation Bio, a company focused on developing innovative genetic medicines. He has been with Generation Bio since its inception in 2017, initially taking on roles that included Senior Vice President and Head of Corporate Development before his promotion to Chief Strategy Officer in September 2022.14

Professional Background

• Education: Samayoa holds dual Bachelor of Science degrees in Biological Engineering and Physics from the Massachusetts Institute of Technology (MIT). He earned his Ph.D. in Systems Biology from the University of California, San Diego, where he was recognized as a National Science Foundation graduate research fellow.134

• Previous Experience:

  • He was a Principal at Atlas Venture, where he co-founded Generation Bio and focused on building novel platform therapeutics companies. He also co-founded Dyne Therapeutics during this time.134
  • Prior to his venture capital roles, Samayoa worked at Merck as the Director of the MRL Ventures Fund, where he led investments in early-stage companies such as Alector and Translate Bio.13
  • He has also been involved with several startups as an associate at Flagship Pioneering, contributing to companies like Codiak BioSciences and Indigo Ag.24

Contributions to Generation Bio

At Generation Bio, Samayoa has played a crucial role in shaping the company's corporate strategy and business development efforts. His work focuses on advancing non-viral DNA therapeutics and targeted delivery systems, which are designed to provide durable treatments for genetic diseases.13 His leadership is pivotal in integrating various strategic activities to maximize the potential of Generation Bio's innovative technologies.14

Samayoa's extensive background in biotechnology, venture capital, and strategic development positions him as a key leader in the advancement of genetic medicine.